Bajaj Healthcare Limited has announced the reappointment of Sajankumar Bajaj as Chairman and Managing Director, ensuring leadership continuity at the pharmaceutical company.

Leadership Reappointment

The company's board has decided to continue with Sajankumar Bajaj's leadership by reappointing him to the dual role of Chairman and Managing Director. This decision reflects the board's confidence in his strategic vision and management capabilities.

Company Overview

Bajaj Healthcare Limited operates in the pharmaceuticals sector and is classified as a small-cap company. The reappointment of its key leadership position indicates stability in the company's management structure.

Strategic Continuity

The reappointment ensures that the company maintains its strategic direction under experienced leadership. Sajankumar Bajaj's continued role as Chairman and Managing Director provides operational consistency for the pharmaceutical company's ongoing business activities.

Bajaj Healthcare Limited delivered exceptional financial performance in Q3, with net profit rising 34.20% year-on-year to ₹15.67 crores, compared with ₹11.72 crores in the corresponding quarter last year. The pharmaceutical company's board of directors approved the quarterly results on January 16, 2026, showcasing robust operational performance and improved margin efficiency.

Strong Revenue Growth Drives Q3 Performance

The company's quarterly performance demonstrated substantial improvement across multiple parameters, with revenue and profitability showing remarkable growth:

Revenue for the quarter increased 31.31% to ₹161.22 crores, up from ₹122.79 crores in Q3 of the previous financial year. The revenue surge was primarily driven by improved operational efficiency and market expansion. EBITDA grew at a faster pace of 42.13% to ₹30.70 crores, reflecting better cost control and operating leverage.

Margin Expansion Highlights Operational Efficiency

Operating margin expanded significantly to 19.03% from 17.62% year-on-year, indicating improved profitability despite ongoing cost pressures across the sector. The EBITDA margin improvement of 141 basis points reflects enhanced cost management and operational leverage. Total income for the quarter reached ₹162.87 crores compared to ₹125.17 crores in the corresponding quarter of the previous year.

Nine-Month Performance Shows Consistent Growth

For the nine-month period ended December 31, 2025, Bajaj Healthcare maintained its growth trajectory:

The nine-month results reflect sustained business momentum with revenue crossing ₹450 crores and net profit showing strong double-digit growth.

Leadership Continuity Through Executive Re-appointments

The board approved the re-appointment of four key executive directors for three-year terms:

All re-appointments are subject to shareholder approval through postal ballot. The leadership team brings decades of combined experience in pharmaceuticals, finance, marketing, and operations.

Market Performance and Business Outlook

Bajaj Healthcare shares closed at ₹389.30, down ₹4.85, or 1.23%, on January 16, 2026. The company operates primarily in the pharmaceuticals segment, dealing with formulations and active pharmaceutical ingredients. The strong Q3 performance underscores steady growth across key financial metrics, positioning the company well for the remainder of the financial year.